Tenderwize
Retour à la recherche

Pharmaceuticals with active substance Erythropoietin (ATC: B03XA01 - strength over 10,000 IU per dosage unit)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Aug 30, 2026 · 2 days left·Open·Supplies
Titre original de l'avis

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Erythropoietin (ATC: B03XA01 - in der Wirkstärke über 10.000 IE je Dosiereinheit)

70/100

Score d'opportunité

PromisingLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

70 / 100

Complexité

20 / 100

Facteurs de risque

AOK may terminate agreements early if exclusive contracts are tendered for the same active substance during the contrac...

No guaranteed volume; actual sales depend on prescription behavior and number of participants.

Submission deadline in 2 days

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Strong opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Supply of Erythropoietin pharmaceuticals (ATC B03XA01, >10,000 IU per dose unit) under non-exclusive discount agreements.
  • Open-house model allowing any eligible pharmaceutical company to participate at any time.
Afficher le résumé complet

This is an open-house model for non-exclusive discount agreements on Erythropoietin pharmaceuticals (strength >10,000 IU per dose unit) with AOK Sachsen-Anhalt. Any eligible pharmaceutical company can conclude a contract at any time under uniform conditions. The contract runs from earliest 01.11.2024 to 31.10.2026 (max 24 months). No estimated value or guaranteed volume is provided. The tender is not a public procurement under GWB but published for transparency.

Risques

AOK may terminate agreements early if exclusive contracts are tendered for the same active substance during the contrac...

No guaranteed volume; actual sales depend on prescription behavior and number of participants.

Submission deadline in 2 days

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company or consortium of pharmaceutical companies.

Administrative

  • Must request and submit completed participation documents and signed contract.
  • Must meet uniform contract conditions (not specified in detail).

Critères d'attribution

Lot 1

No competitive award; contract available to all eligible participants.

Acheteur

Localisation

Magdeburg, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE258393558

Activité

Health

Lots (1)

LOT-0001

Pharmaceuticals with active substance Erythropoietin (ATC: B03XA01 - strength over 10,000 IU per dosage unit)

Conclusion of non-exclusive discount agreements for finished medicinal products containing Erythropoietin (ATC: B03XA01, strength >10,000 IU) under an open-house model. Any eligible pharmaceutical company can join at any time with standard contract terms. No exclusivity.

SuppliesEU fundedElectronic submission

Localisation

DEE03, Germany

Durée

2 YEAR

Catégorie

Pharmaceutical products

Critères d'attribution

No competitive award; contract available to all eligible participants.

Date limite

Deadline Aug 30, 2026

Détails de la procédure

Date de publication
19 Sep 2024
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
567828-2024

Documents (1)

Appels d'offres similaires